Chongqing Zhifei Biological Products Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Chongqing Zhifei Biological Products kazanç ve gelirin sırasıyla yıllık 43.1% ve 14.6% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 41.4% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 18.9% olacağı tahmin edilmektedir.

Anahtar bilgiler

43.1%

Kazanç büyüme oranı

41.4%

EPS büyüme oranı

Biotechs kazanç büyümesi	43.1%
Gelir büyüme oranı	14.6%
Gelecekteki özkaynak getirisi	18.9%
Analist kapsamı	Good
Son güncelleme	27 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

These 4 Measures Indicate That Chongqing Zhifei Biological Products (SZSE:300122) Is Using Debt Reasonably Well

Nov 26

Chongqing Zhifei Biological Products Co., Ltd.'s (SZSE:300122) Share Price Boosted 45% But Its Business Prospects Need A Lift Too

Sep 30

Chongqing Zhifei Biological Products Co., Ltd. (SZSE:300122) Analysts Are More Bearish Than They Used To Be

Sep 03

Calculating The Fair Value Of Chongqing Zhifei Biological Products Co., Ltd. (SZSE:300122)

Aug 23

We Think Chongqing Zhifei Biological Products (SZSE:300122) Can Stay On Top Of Its Debt

Jul 26

Why Investors Shouldn't Be Surprised By Chongqing Zhifei Biological Products Co., Ltd.'s (SZSE:300122) Low P/E

May 21

Earnings Miss: Chongqing Zhifei Biological Products Co., Ltd. Missed EPS By 35% And Analysts Are Revising Their Forecasts

Apr 26

Is Chongqing Zhifei Biological Products (SZSE:300122) A Risky Investment?

Mar 26

Kazanç ve Gelir Büyüme Tahminleri

SZSE:300122 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (CNY Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	46,852	8,636	11,072	9,798	8
12/31/2025	51,894	9,639	6,738	8,665	12
12/31/2024	32,201	3,312	1,986	13,525	2
9/30/2024	36,432	3,690	2,331	3,346	N/A
6/30/2024	46,731	6,044	5,500	6,512	N/A
3/31/2024	53,141	7,496	4,665	5,763	N/A
12/31/2023	52,918	8,070	7,862	8,996	N/A
9/30/2023	49,712	8,462	2,476	3,586	N/A
6/30/2023	44,356	8,070	4,357	5,546	N/A
3/31/2023	40,596	7,648	2,951	4,266	N/A
1/1/2023	38,264	7,539	536	1,989	N/A
9/30/2022	36,647	7,412	-360	1,175	N/A
6/30/2022	35,835	8,447	-1,151	596	N/A
3/31/2022	35,567	11,193	3,452	5,305	N/A
12/31/2021	30,652	10,209	6,575	8,508	N/A
9/30/2021	25,969	9,226	7,515	9,350	N/A
6/30/2021	21,368	7,287	8,050	9,627	N/A
3/31/2021	16,482	3,723	2,691	3,868	N/A
12/31/2020	15,190	3,301	2,670	3,497	N/A
9/30/2020	13,971	3,082	2,554	3,272	N/A
6/30/2020	12,542	2,724	1,038	1,604	N/A
3/31/2020	10,928	2,381	691	1,318	N/A
12/31/2019	10,587	2,366	794	1,367	N/A
9/30/2019	9,400	2,128	598	1,145	N/A
6/30/2019	8,195	1,916	247	764	N/A
3/31/2019	6,684	1,694	-422	82	N/A
12/31/2018	5,228	1,451	106	586	N/A
9/30/2018	4,068	1,234	-326	98	N/A
6/30/2018	2,969	943	N/A	170	N/A
3/31/2018	2,019	632	N/A	298	N/A
12/31/2017	1,343	432	N/A	204	N/A
9/30/2017	942	311	N/A	207	N/A
6/30/2017	707	192	N/A	126	N/A
3/31/2017	464	34	N/A	87	N/A
12/31/2016	446	33	N/A	90	N/A
9/30/2016	431	44	N/A	253	N/A
6/30/2016	512	101	N/A	207	N/A
3/31/2016	660	209	N/A	265	N/A
12/31/2015	713	197	N/A	223	N/A
9/30/2015	779	172	N/A	143	N/A
6/30/2015	805	160	N/A	165	N/A
3/31/2015	835	153	N/A	167	N/A
12/31/2014	801	148	N/A	161	N/A
9/30/2014	777	136	N/A	153	N/A
6/30/2014	735	124	N/A	179	N/A
3/31/2014	758	132	N/A	157	N/A
12/31/2013	780	130	N/A	222	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 300122 'nin tahmini kazanç büyümesi (yıllık 43.1% ) tasarruf oranının ( 2.8% ) üzerindedir.

Kazançlar ve Piyasa: 300122 şirketinin kazançlarının (yıllık 43.1% ) CN pazarından (yıllık 26.2% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: 300122 şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artması bekleniyor.

Gelir ve Pazar: 300122 şirketinin gelirinin (yıllık 14.6% ) CN pazarından (yıllık 13.8% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: 300122 şirketinin gelirinin (yıllık 14.6% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 300122 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 18.9 %).

Chongqing Zhifei Biological Products Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus revenue estimates fall by 23%

Consensus revenue estimates fall by 27%

Price target decreased by 22% to CN¥38.55

Price target decreased by 9.7% to CN¥49.16

Price target decreased by 8.3% to CN¥53.66

Consensus EPS estimates fall by 20%

Recent updates

These 4 Measures Indicate That Chongqing Zhifei Biological Products (SZSE:300122) Is Using Debt Reasonably Well

Consensus revenue estimates fall by 23%

Investor sentiment deteriorates as stock falls 24%

Insufficient new directors

Chongqing Zhifei Biological Products Co., Ltd.'s (SZSE:300122) Share Price Boosted 45% But Its Business Prospects Need A Lift Too

Chongqing Zhifei Biological Products Co., Ltd. to Report Q3, 2024 Results on Oct 29, 2024

New minor risk - Share price stability

Investor sentiment improves as stock rises 34%

Chongqing Zhifei Biological Products Co., Ltd. Approves Election of Zhang Xinrong as Independent Director

Consensus revenue estimates fall by 27%

Price target decreased by 22% to CN¥38.55

Chongqing Zhifei Biological Products Co., Ltd. (SZSE:300122) Analysts Are More Bearish Than They Used To Be

Calculating The Fair Value Of Chongqing Zhifei Biological Products Co., Ltd. (SZSE:300122)

Now 22% overvalued

Chongqing Zhifei Biological Products Co., Ltd. Announces Final Dividend on A Shares, Payable on 08 August 2024

Price target decreased by 9.7% to CN¥49.16

We Think Chongqing Zhifei Biological Products (SZSE:300122) Can Stay On Top Of Its Debt

Price target decreased by 8.3% to CN¥53.66

Chongqing Zhifei Biological Products Co., Ltd. to Report First Half, 2024 Results on Aug 30, 2024

Why Investors Shouldn't Be Surprised By Chongqing Zhifei Biological Products Co., Ltd.'s (SZSE:300122) Low P/E

Consensus EPS estimates fall by 20%

Earnings Miss: Chongqing Zhifei Biological Products Co., Ltd. Missed EPS By 35% And Analysts Are Revising Their Forecasts

Price target decreased by 7.4% to CN¥65.91

Chongqing Zhifei Biological Products Co., Ltd., Annual General Meeting, Jun 18, 2024

Investor sentiment deteriorates as stock falls 15%

Chongqing Zhifei Biological Products Co., Ltd. to Report Q1, 2024 Results on Apr 23, 2024

Is Chongqing Zhifei Biological Products (SZSE:300122) A Risky Investment?

Chongqing Zhifei Biological Products Co., Ltd. (SZSE:300122) announces an Equity Buyback for CNY 500 million worth of its shares.

Investor sentiment improves as stock rises 16%

Chongqing Zhifei Biological Products Co., Ltd. to Report Fiscal Year 2023 Results on Apr 23, 2024

Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

New minor risk - Share price stability

Investor sentiment improves as stock rises 20%

Chongqing Zhifei Biological Products Co., Ltd. to Report Q3, 2023 Results on Oct 27, 2023

Price target decreased by 8.2% to CN¥67.08

Price target decreased by 7.7% to CN¥72.05

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Investor sentiment deteriorates as stock falls 32%

EVE Energy Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 16 June 2023

Consensus revenue estimates increase by 16%

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Investor sentiment improved over the past week

Price target decreased to CN¥121

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improved over the past week

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Chongqing Zhifei Biological Products Co., Ltd. Announces Final Dividend on A Shares for the Year 2021, Payable on July 15, 2022

Investor sentiment improved over the past week

Chongqing Zhifei Biological Products Co., Ltd. Approves Cash Dividend for the Year 2021

Consensus forecasts updated

Price target decreased to CN¥148

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Price target decreased to CN¥193

Consensus EPS estimates increase by 10%

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Third quarter 2021 earnings released: EPS CN¥1.82 (vs CN¥0.61 in 3Q 2020)

Insufficient new directors

Insufficient new directors

Second quarter 2021 earnings released: EPS CN¥2.85 (vs CN¥0.62 in 2Q 2020)

Investor sentiment deteriorated over the past week

Price target increased to CN¥219

Consensus revenue estimates increase to CN¥26.1b

First quarter 2021 earnings released: EPS CN¥0.59 (vs CN¥0.32 in 1Q 2020)

Investor sentiment deteriorated over the past week

Chongqing Zhifei Biological Products Co., Ltd. to Report Fiscal Year 2020 Results on Apr 20, 2021

New 90-day high: CN¥167

Market bids up stock over the past week